BD Q1 FY25 earnings: Strong growth, higher guidance, and biosciences separation strategy
Becton, Dickinson and Company, a global leader in medical technology, reported a 9.8% year-over-year revenue increase in its first-quarter fiscal 2025 earnings, reaching $5.2 billion. ... Read More
BD settles SEC investigation with $175m agreement, no financial restatements required
Becton, Dickinson and Company (NYSE: BDX), a global leader in medical technology, has announced the resolution of a longstanding SEC investigation settlement involving its BD ... Read More